icon- folder.gif   Conference Reports for NATAP  
 
  International AIDS Conference
Durban, South Africa
July 18-22 2016
 Back grey_arrow_rt.gif
 
 
 
IAC/Durban 2016 - Key HIV HAART Studies, TB
 
 
  IAC: Switching to Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination (DTG/ABC/3TC FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks - (07/25/16)
 
IAC: Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results - (07/29/16)
 
IAC: Superior Efficacy of Dolutegravir/Abacavir/Lamivudine FDC Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine FDC in Treatment-Naive Women With HIV-1 Infection: ARIA Study - (07/26/16)
 
IAC: Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 48 Results - (07/25/16)
 
IAC: Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naïve patients 48 Week Results of the PADDLE trial. - (07/29/16)
 
IAC: Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/28/16)
 
IAC: Enhanced Infection Prophylaxis Cuts Mortality 25% in ART Starters With Low CD4s......Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial.
 
IAC: Increased risk of suicidal behaviour with use of efavirenz: Results from the START Trial - (07/26/16)
 
IAC: 12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial - (07/26/16)
 
IAC: Randomized trial of stopping or continuing ART among post-partum women with pre-ART CD4 >400 cells/mm3 (PROMISE 1077HS) ...." Shows Mixed Results" - Mark Mascolini - (07/22/16)
 
TB - IAC: Daily is better than thrice-weekly ATT in HIV patients with culture confirmed pulmonary TB,- a RCT from South India (CTRI-476/09, NCT00933790 ) Study initiation date : 14.09.2009 - (07/29/16)
 
IAC: Adherence With Combination Antiretroviral Therapy (cART): Do Challenges Still Persist? "31% non-adherent" - (08/03/16)
 
IAC: The impact of Universal Test and Treat on HIV incidence in a rural South African population ....Poor Linkage to Care Undermines Test-and-Treat in South African Trial.... - Mark Mascolini (07/27/16)